Patent classifications
C07K1/02
Method for producing a condensed adhesive phase of silk fusion proteins
The present invention is directed to a method for producing a condensed phase of a silk fusion protein, the method comprising the steps of preparing a solution of a silk fusion protein in an aqueous medium and concentrating said silk fusion protein in said aqueous medium, wherein said fusion protein is isolated from a recombinant production host and comprises a silk-like protein sequence and two separate non-silk terminal module sequences, such as cellulose binding modules, SpyCatcher domains, tenth type III module of Fibronectin, gamma-crystallin D, flanking said silk-like protein sequence; wherein the method is performed so that said silk fusion protein is not precipitated and subsequently dissolved to said aqueous medium. The present invention is also directed to using such fusion proteins as adhesives.
Method for producing a condensed adhesive phase of silk fusion proteins
The present invention is directed to a method for producing a condensed phase of a silk fusion protein, the method comprising the steps of preparing a solution of a silk fusion protein in an aqueous medium and concentrating said silk fusion protein in said aqueous medium, wherein said fusion protein is isolated from a recombinant production host and comprises a silk-like protein sequence and two separate non-silk terminal module sequences, such as cellulose binding modules, SpyCatcher domains, tenth type III module of Fibronectin, gamma-crystallin D, flanking said silk-like protein sequence; wherein the method is performed so that said silk fusion protein is not precipitated and subsequently dissolved to said aqueous medium. The present invention is also directed to using such fusion proteins as adhesives.
METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF
Disclosed herein, inter alia, are methods of making and using streptogramin compositions.
METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF
Disclosed herein, inter alia, are methods of making and using streptogramin compositions.
Production Method for Metal-Encapsulated Cage-Like Protein
The present invention provides a production method for a metal-encapsulated cage-like protein, comprising a step of introducing a metal element into a cage-like protein in the presence of a polysaccharide to produce a metal-encapsulated cage-like protein that encapsulates the metal element.
Production Method for Metal-Encapsulated Cage-Like Protein
The present invention provides a production method for a metal-encapsulated cage-like protein, comprising a step of introducing a metal element into a cage-like protein in the presence of a polysaccharide to produce a metal-encapsulated cage-like protein that encapsulates the metal element.
A PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE
A process for preparing a GLP-1 or GLP-2 peptide, said process comprising coupling in solution at least a first fragment and at least a second fragment, wherein the coupling comprises reacting the carboxy terminal amino acid of the first fragment with the amino terminal amino acid of the second fragment, and wherein the carboxy terminal amino acid of the first fragment is other than a Gly residue
A PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE
A process for preparing a GLP-1 or GLP-2 peptide, said process comprising coupling in solution at least a first fragment and at least a second fragment, wherein the coupling comprises reacting the carboxy terminal amino acid of the first fragment with the amino terminal amino acid of the second fragment, and wherein the carboxy terminal amino acid of the first fragment is other than a Gly residue
PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES
The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-26-Dmt-Lys-Phe-NH.sub.2.
PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES
The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-26-Dmt-Lys-Phe-NH.sub.2.